Cholecystokinin Receptor Pharmacology

Overview

Cholecystokinin (CCK) is a gastrointestinal peptide hormone and neuropeptide existing in multiple bioactive forms—primarily CCK-8 (octapeptide), CCK-33, and CCK-58—generated by proteolytic processing of preprocholecystokinin. CCK exerts its physiological effects through two G-protein-coupled receptors: CCK-A (CCK1R) and CCK-B (CCK2R), which share approximately 50% sequence homology but exhibit distinct tissue distribution, ligand selectivity, and pharmacological profiles.

CCK-A Receptor (CCK1R)

The CCK-A receptor is predominantly expressed in peripheral tissues including the gastrointestinal tract (gallbladder, pyloric sphincter, pancreatic acinar cells) and select central nervous system nuclei (area postrema, nucleus tractus solitarius). CCK-A receptors display high affinity for sulfated CCK octapeptide (CCK-8S) and sulfated cholecystokinin fragments, with Kd values in the low nanomolar range. Unsulfated CCK-8 binds with approximately 100-fold lower affinity, illustrating the critical role of sulfate ester group in receptor recognition.

Satiety Signaling

Peripheral CCK-8 activates CCK-A receptors on vagal afferent fibers innervating the duodenal and jejunal mucosa, transmitting satiety signals to brainstem feeding centers. The satiety effect is characterized by meal termination rather than long-term energy balance regulation—a distinction that initially dampened pharmaceutical interest in CCK-A agonists for obesity treatment. However, combination approaches integrating CCK-A modulation with GLP-1 receptor agonism have renewed interest in this pathway.

Gastrointestinal Motility

CCK-A receptor activation contracts gallbladder smooth muscle, relaxes the sphincter of Oddi, and modulates gastric emptying through inhibitory action on pyloric tone. These actions are exploited therapeutically in diagnostic cholecystokinin-HIDA imaging studies that evaluate gallbladder ejection fraction.

CCK-B Receptor (CCK2R)

The CCK-B receptor is expressed throughout the central nervous system with particularly high density in limbic structures (amygdala, hippocampus, cortex) and is the predominant CCK receptor isoform in the brain. CCK-B receptors bind both sulfated and unsulfated CCK fragments with comparable affinity, as well as the neuropeptide gastrin, which shares the C-terminal pentapeptide sequence Trp-Met-Asp-Phe-NH₂ with CCK.

Anxiogenic and Antipsychotic Effects

Central CCK-8 acting at CCK-B receptors functions as an endogenous anxiogenic neuropeptide. Intracerebroventricular administration of CCK-4 triggers acute panic attacks in humans, a response blocked by selective CCK-B antagonists. This observation stimulated development of CCK-B antagonists as potential anxiolytic and antipsychotic agents, although clinical trials have yielded mixed results, likely due to redundant anxiety-related signaling pathways.

Modulation of Dopaminergic Transmission

CCK-B receptors co-localize with dopamine D2 receptors in mesolimbic and mesocortical pathways. CCK co-released with dopamine modulates dopaminergic neurotransmission, and CCK-B antagonism has been shown to enhance dopamine release in prefrontal cortical regions, suggesting potential utility as an adjunctive antipsychotic strategy.

Therapeutic Applications and Drug Development

CCK-A agonists have been explored as appetite suppressants, though clinical efficacy has been limited by tachyphylaxis and gastrointestinal side effects. CCK-B antagonists investigated as anxiolytics include CI-988 and L-365,260, both of which demonstrated preclinical anxiolytic activity. Mixed clinical outcomes have redirected focus toward partial agonists and allosteric modulators that fine-tune rather than abolish CCK-B signaling. Dual CCK-A/CCK-B peptide ligands incorporating optimized pharmacophore elements represent an emerging design strategy.

Conclusion

The CCK receptor system exemplifies how a single peptide family can produce diverse physiological effects through receptor subtype-specific signaling. Continued structural and pharmacological characterization of CCK receptors will inform the development of more selective and clinically effective modulators.